1. Home
  2. CWEN vs LQDA Comparison

CWEN vs LQDA Comparison

Compare CWEN & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearway Energy Inc. Class C

CWEN

Clearway Energy Inc. Class C

N/A

Current Price

$30.24

Market Cap

6.3B

Sector

Utilities

ML Signal

N/A

LQDA

Liquidia Corporation

N/A

Current Price

$27.50

Market Cap

5.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CWEN
LQDA
Founded
2012
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.5B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
CWEN
LQDA
Price
$30.24
$27.50
Analyst Decision
Strong Buy
Buy
Analyst Count
14
8
Target Price
$41.50
★ $49.67
AVG Volume (30 Days)
1.1M
★ 2.9M
Earning Date
11-03-2026
11-02-2026
Dividend Yield
★ 6.34%
N/A
EPS Growth
11.94
★ 51.81
EPS
0.75
★ 1.26
Revenue
★ $1,429,000,000.00
$158,320,000.00
Revenue This Year
$18.76
$323.17
Revenue Next Year
$12.21
$10.30
P/E Ratio
$39.93
★ $22.24
Revenue Growth
4.23
★ 1031.18
52 Week Low
$28.57
$21.97
52 Week High
$41.74
$93.61

Technical Indicators

Market Signals
Indicator
CWEN
LQDA
Relative Strength Index (RSI) 47.49 21.68
Support Level $30.00 $22.31
Resistance Level $31.23 $42.62
Average True Range (ATR) 0.64 3.24
MACD 0.16 -3.63
Stochastic Oscillator 62.74 10.11

Price Performance

Historical Comparison
CWEN
LQDA

About CWEN Clearway Energy Inc. Class C

Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and the owner of modern, sustainable, and long-term contracted assets across North America. The company segments its operations into Flexible Generation, Renewables & Storage, and Corporate divisions. The majority of its revenue is generated from the Renewables & Storage segment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: